COVID-19 has emerged as a pandemic leading to a global public health crisis of
unprecedented morbidity. A comprehensive insight into the imaging of COVID-19 has …

Pulmonary embolism (PE) is the third-leading cause of cardiovascular mortality and the
second-leading cause of death in cancer patients. The clinical efficacy of thrombolysis for …

Importance The use of warfarin to prevent thromboembolism in patients with infective
endocarditis (IE) remains controversial due to potentially increased bleeding risks. Design …

VTE remains a significant health care challenge, demanding vigilance, knowledge, and a
multidisciplinary approach. Treatment and prophylaxis recommendations are based on …

Introduction Although older adults represent a significant proportion of patients with venous
thromboembolism (VTE), the data on the impact of age-related differences in the clinical …

In patients with interstitial lung disease (ILD), the risk of pulmonary embolism (PE) is
increased; however, distinguishing between PE and ILD exacerbation can be difficult …

Background Morbidity and mortality for acute pulmonary embolism (PE) remain high.
Therapies such as catheter-directed thrombolysis may improve outcomes, but these are …

Data on the optimal diagnostic management of pregnant women with suspected pulmonary
embolism are limited. Despite a lack of compelling evidence in some practices, clinical …

D-dimer is a multifaceted biomarker of concomitant activation of coagulation and fibrinolysis,
which is routinely used for ruling out pulmonary embolism (PE) and/or deep vein thrombosis …

D-dimer, a soluble fibrin degradation product that originates from plasmin-induced
degradation of cross-linked fibrin, is an important biomarker of coagulation activation and …